Next Article in Journal
Diagnosis Assistance in Colposcopy by Segmenting Acetowhite Epithelium Using U-Net with Images before and after Acetic Acid Solution Application
Next Article in Special Issue
A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target
Previous Article in Journal
An Explainable Classification Method Based on Complex Scaling in Histopathology Images for Lung and Colon Cancer
Previous Article in Special Issue
A Systematic Review of Diagnostic and Prognostic Biomarkers for Head and Neck Cancer of Unknown Primary: An Unmet Clinical Need
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 9
10.3390/diagnostics13091595
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

by
Giuseppe Lamberti
1,2,
Natalie Prinzi
3,
Alberto Bongiovanni
4,
Mariangela Torniai
5,
Elisa Andrini
1,
Dario de Biase
6,7,
Deborah Malvi
8,
Mirta Mosca
1,
Rossana Berardi
5,
Toni Ibrahim
4,
Sara Pusceddu
3 and
Davide Campana
1,2,*
1
Department of Medical or Surgical Sciences, University of Bologna, 40126 Bologna, Italy
2
Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria Sant’Orsola-Malpighi di Bologna, 40138 Bologna, Italy
3
Medical Oncology, Foundation IRCCS National Cancer Institute, 20133 Milano, Italy
4
Osteoncology and Rare Tumor Center (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
5
Department of Oncology, Università Politecnica delle Marche-AOU delle Marche, 60126 Ancona, Italy
6
Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy
7
Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
8
Pathology Unit, IRCCS Azienda-Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(9), 1595; https://doi.org/10.3390/diagnostics13091595
Submission received: 3 April 2023 / Revised: 23 April 2023 / Accepted: 28 April 2023 / Published: 29 April 2023
(This article belongs to the Special Issue Genomic Approach for Diagnosis, Prognosis and Therapy Prediction in Cancer Research)
Browse Figures
Review Reports Versions Notes

Abstract

Background: Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are poorly characterized in terms of molecular features and response to treatments. Methods: Patients with G3 GEP-NET were included if they received capecitabine and temozolomide (CAPTEM) or oxaliplatin with either 5-fluorouracile (FOLFOX) or capecitabine (XELOX) as first-line treatment (chemotherapy cohort). G3 NET which successfully undergone next-generation sequencing (NGS) were included in the NGS cohort. Results: In total, 49 patients were included in the chemotherapy cohort: 15 received CAPTEM and 34 received FOLFOX/XELOX. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were 42.9%, 9.0 months, and 33.6 months, respectively. Calculating a Ki67 cutoff using ROC curve analysis, tumors with Ki67 ≥ 40% had lower ORR (51.2% vs. 0%; p = 0.007) and shorter PFS (10.6 months vs. 4.4 months; p < 0.001) and OS (49.4 months vs. 10.0 months; p = 0.023). In patients who received FOLFOX/XELOX as a first-line treatment, ORR, PFS, and OS were 38.2%, 7.9 months, and 30.0 months, respectively. In the NGS cohort (N = 13), the most mutated genes were DAXX/ATRX (N = 5, 38%), MEN1 (N = 4, 31%), TP53 (N = 4, 31%), AKT1 (N = 2, 15%), and PIK3CA (N = 1, 8%). Conclusions: FOLFOX/XELOX chemotherapy is active as the first-line treatment of patients with G3 GEP-NET. The mutational landscape of G3 NET is more similar to well-differentiated NETs than NECs.
Keywords: NET; G3; FOLFOX; XELOX; CAPTEM; NGS; genomic; DAXX; ATRX NET; G3; FOLFOX; XELOX; CAPTEM; NGS; genomic; DAXX; ATRX

Share and Cite

MDPI and ACS Style

Lamberti, G.; Prinzi, N.; Bongiovanni, A.; Torniai, M.; Andrini, E.; Biase, D.d.; Malvi, D.; Mosca, M.; Berardi, R.; Ibrahim, T.; et al. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics 2023, 13, 1595. https://doi.org/10.3390/diagnostics13091595

AMA Style

Lamberti G, Prinzi N, Bongiovanni A, Torniai M, Andrini E, Biase Dd, Malvi D, Mosca M, Berardi R, Ibrahim T, et al. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics. 2023; 13(9):1595. https://doi.org/10.3390/diagnostics13091595

Chicago/Turabian Style

Lamberti, Giuseppe, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim, and et al. 2023. "Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)" Diagnostics 13, no. 9: 1595. https://doi.org/10.3390/diagnostics13091595

APA Style

Lamberti, G., Prinzi, N., Bongiovanni, A., Torniai, M., Andrini, E., Biase, D. d., Malvi, D., Mosca, M., Berardi, R., Ibrahim, T., Pusceddu, S., & Campana, D. (2023). Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics, 13(9), 1595. https://doi.org/10.3390/diagnostics13091595

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop